Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

As the gene therapy field advances, speed-to-market is becoming more and more essential. The necessary reduction in development timelines can be realized by leveraging platform-based tools and technical expertise. Platforms for clinical manufacturing of AAV offer the advantage of a pre-designed template tailored to fast-track products through development and into GMP manufacturing. In addition, design of experiment elution optimization studies can enable advantageous gains in recovery. In this article, an off-the-shelf solution for AAV production developed by a CDMO is introduced, with a particular focus on the AAV capture steps of the downstream process. Case study data is presented to explore the considerations for the use of platform purification tools in AAV manufacturing.

Please enter your email to access content Read now